Literature DB >> 21981141

Impact of ageing on biological features of bone marrow stromal cells (BMSC) in cell transplantation therapy for CNS disorders: functional enhancement by granulocyte-colony stimulating factor (G-CSF).

Yasuhiro Chiba1, Satoshi Kuroda, Toshiya Osanai, Hideo Shichinohe, Kiyohiro Houkin, Yoshinobu Iwasaki.   

Abstract

This study was designed to clarify the effects of donor age on biological features of bone marrow stromal cells (BMSC), one of the candidates for cell transplantation therapy for CNS disorders, because many aged patients might require such therapy. This study was also aimed to test whether ex vivo treatments with granulocyte-colony stimulating factor (G-CSF) could modify biological properties of BMSC from aged donors and enhance its therapeutic effects in an animal model of traumatic brain injury. The BMSC were harvested from young (6-week-old) and aged (100-week-old) rats. The ageing significantly increased the senescence-associated β-galactosidase (SA-β-gal) activity of the cultured BMSC, and decreased their proliferative capacity and production of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). As the next step, the rats were subjected to brain freezing injury by applying liquid nitrogen onto the neocortex through the thinned skull. The 6-week BMSC, 100-week BMSC, G-CSF-treated 100-week BMSC or vehicle were stereotactically injected into the ipsilateral striatum at 7 days post-injury. Transplantation of the 6-week BMSC, but not 100-week BMSC, significantly improved locomotor function. However, treatment of the 100-week BMSC with 0.1 µmol of G-CSF significantly improved their proliferation activity and growth factor production, and recovered therapeutic effects in the injured brain. In conclusion, donor age may largely determine biological aspects of BMSC. G-CSF may contribute to improve the outcome of BMSC transplantation therapy for CNS disorders in aged patients.
© 2011 Japanese Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21981141     DOI: 10.1111/j.1440-1789.2011.01255.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  15 in total

Review 1.  Stem cell therapy for cerebral ischemia: from basic science to clinical applications.

Authors:  Koji Abe; Toru Yamashita; Shunya Takizawa; Satoshi Kuroda; Hiroyuki Kinouchi; Nobutaka Kawahara
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-18       Impact factor: 6.200

2.  Assessment of chondrogenic differentiation potential of autologous activated peripheral blood stem cells on human early osteoarthritic cancellous tibial bone scaffold.

Authors:  T Turajane; T Thitiset; S Honsawek; U Chaveewanakorn; J Aojanepong; K I Papadopoulos
Journal:  Musculoskelet Surg       Date:  2013-11-01

Review 3.  Enhancing the Therapeutic Potential of Mesenchymal Stem Cells with the CRISPR-Cas System.

Authors:  Daniel Mendes Filho; Patrícia de Carvalho Ribeiro; Lucas Felipe Oliveira; Ana Luiza Romero Terra Dos Santos; Ricardo Cambraia Parreira; Mauro Cunha Xavier Pinto; Rodrigo Ribeiro Resende
Journal:  Stem Cell Rev Rep       Date:  2019-08       Impact factor: 5.739

4.  miR-148b-3p, miR-337-5p and miR-423-5p expression in alveolar ridge atrophy and their roles in the proliferation and apoptosis of OMMSCs.

Authors:  Sefei Yang; Jun Guo; Lei Zhou; Helin Xing; Xianli Wang; Chaofang Dong
Journal:  Exp Ther Med       Date:  2018-10-11       Impact factor: 2.447

5.  G-CSF and hypoxic conditioning improve the proliferation, neural differentiation and migration of canine bone marrow mesenchymal stem cells.

Authors:  Jing Yu; Xing-Long Liu; Qi-Guang Cheng; Shan-Shan Lu; Xiao-Quan Xu; Qing-Quan Zu; Sheng Liu
Journal:  Exp Ther Med       Date:  2016-07-20       Impact factor: 2.447

6.  Age of donor of human mesenchymal stem cells affects structural and functional recovery after cell therapy following ischaemic stroke.

Authors:  Susumu Yamaguchi; Nobutaka Horie; Katsuya Satoh; Takeshi Ishikawa; Tsuyoshi Mori; Hajime Maeda; Yuhtaka Fukuda; Shunsuke Ishizaka; Takeshi Hiu; Yoichi Morofuji; Tsuyoshi Izumo; Noriyuki Nishida; Takayuki Matsuo
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-15       Impact factor: 6.200

7.  Priming with a Combination of FGF2 and HGF Restores the Impaired Osteogenic Differentiation of Adipose-Derived Stem Cells.

Authors:  Jeong Seop Park; Doyoung Kim; Hyun Sook Hong
Journal:  Cells       Date:  2022-06-27       Impact factor: 7.666

8.  Platelet lysate and granulocyte-colony stimulating factor serve safe and accelerated expansion of human bone marrow stromal cells for stroke therapy.

Authors:  Tomohiro Yamauchi; Hisayasu Saito; Masaki Ito; Hideo Shichinohe; Kiyohiro Houkin; Satoshi Kuroda
Journal:  Transl Stroke Res       Date:  2014-07-26       Impact factor: 6.829

Review 9.  Current Opinion of Bone Marrow Stromal Cell Transplantation for Ischemic Stroke.

Authors:  Satoshi Kuroda
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-03-15       Impact factor: 1.742

10.  Mesenchymal Stem Cell Sheet Promotes Functional Recovery and Palliates Neuropathic Pain in a Subacute Spinal Cord Injury Model.

Authors:  Kazuyoshi Yamazaki; Masahito Kawabori; Toshitaka Seki; Soichiro Takamiya; Kotaro Konno; Masahiko Watanabe; Kiyohiro Houkin; Miki Fujimura
Journal:  Stem Cells Int       Date:  2021-07-09       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.